Advertisement

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis

  • Katalin Gulyas
  • Nora Bodnar
  • Zsofia Nagy
  • Szilvia Szamosi
  • Agnes Horvath
  • Andrea Vancsa
  • Edit Vegh
  • Zoltan Szabo
  • Gabriella Szucs
  • Zoltan Szekanecz
  • Sandor Szanto
Original Paper

Abstract

Objective

The aim of this study was to evaluate the efficacy, reasons for switching and drug survival of TNF-α inhibitors (TNFis) used as first- and second-line drugs in ankylosing spondylitis (AS).

Methods

Data on patients suffering from AS and treated with at least one TNFi between November 2005 and 2013 were extracted retrospectively from the database of a single clinical centre. Beside demographic data, the disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the response rates (BASDAI50), reasons for switching and survival curves of TNFis were analysed in general and in subgroups of patients treated with each of the available TNFis. The reasons for switching were defined as inefficacy, side effects of the given drug, patient’s request and occurrence of extra-articular manifestations.

Results

Altogether, 175 patients were on TNFis and 77 of them received at least two TNFis. The patients’ age at the initiation of the first TNFi was higher among switchers compared to non-switchers (42.5 ± 12.6 vs. 38.8 ± 11.2 years, p = 0.049); otherwise, gender, disease duration and initial disease activity had no influence on the risk of switching. The decrease of the BASDAI was similar among non-switchers and switchers using either the first or second TNFi, but the response rates to the first and second TNFi were worse in switchers than in non-switchers. Following the failure of the first TNFi, the retention on therapy was unfavourable, especially in patients on infliximab after 1 year of treatment. The main reason for switching from the first drug was inefficacy. The frequency of side effects that led to switching was higher in the infliximab group than in patients treated with other agents.

Conclusion

Although the retention rate to a second-line TNFi was somewhat worse than that to the first-line TNFi, the switching of TNFis is a good therapeutic option in AS patients who failed to respond to the first TNFi.

Keywords

Ankylosing spondylitis Anti-tumour necrosis factor-α therapy Switch 

JEL Classification

I190 

Notes

Acknowledgements

This research was supported by the European Union and the State of Hungary co-financed by the European Social Fund in the framework of TÁMOP-4.2.4.A/2-11/1-2012-0001 ‘National Excellence Program’.

References

  1. 1.
    van der Heijde, D., Pangan, A.L., Schiff, M.H., Braun, J., Borofsky, M., Torre, J., et al.: Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann. Rheum. Dis. 67(9), 1218–1221 (2008)PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Davis Jr, J.C., Van der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D.O., et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48(11), 3230–3236 (2003)PubMedCrossRefGoogle Scholar
  3. 3.
    Inman, R.D., Davis Jr, J.C., Heijde, D.v., Diekman, L., Sieper, J., Kim, S.I., et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58(11), 3402–3412 (2008)PubMedCrossRefGoogle Scholar
  4. 4.
    van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52(2), 582–591 (2005)PubMedCrossRefGoogle Scholar
  5. 5.
    Machado, M.A., Barbosa, M.M., Almeida, A.M., de Araújo, V.E., Kakehasi, A.M., Andrade, E.I., et al.: Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol. Int. 33(9), 2199–2213 (2013)PubMedCrossRefGoogle Scholar
  6. 6.
    van der Heijde, D., Sieper, J., Maksymowych, W.P., Dougados, M., Burgos-Vargas, R., Landewé, R., et al.: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70(6), 905–908 (2011)PubMedCrossRefGoogle Scholar
  7. 7.
    Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70(6), 896–904 (2011)PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Elewaut, D., Matucci-Cerinic, M.: Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 48(9), 1029–1035 (2009)CrossRefGoogle Scholar
  9. 9.
    El Maghraoui, A.: Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur. J. Intern. Med. 22(6), 554–560 (2011)PubMedCrossRefGoogle Scholar
  10. 10.
    Baraliakos, X., Listing, J., Fritz, C., Haibel, H., Alten, R., Burmester, G.R., et al.: Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9), 1690–1699 (2011)CrossRefGoogle Scholar
  11. 11.
    Conti, F., Ceccarelli, F., Marocchi, E., Magrini, L., Spinelli, F.R., Spadaro, A., et al.: Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann. Rheum. Dis. 66(10), 1393–1397 (2007)PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Landewé, R., Braun, J., Deodhar, A., Dougados, M., Maksymowych, W.P., Mease, P.J., et al.: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. 73(1), 39–47 (2014)PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Rudwaleit, M., Van den Bosch, F., Kron, M., Kary, S., Kupper, H.: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res. Ther. 12(3), R117 (2010)PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Glintborg, B., Østergaard, M., Krogh, N.S., Tarp, U., Manilo, N., Loft, A.G., et al.: Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann. Rheum. Dis. 72(7), 1149–1155 (2013)PubMedGoogle Scholar
  15. 15.
    Lie, E., van der Heijde, D., Uhlig, T., Mikkelsen, K., Rødevand, E., Koldingsnes, W., et al.: Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann. Rheum. Dis. 70(1), 157–163 (2011)PubMedGoogle Scholar
  16. 16.
    Hodinka, L.: The professional protocol of the Ministry of Health: the use of biological therapies in inflammatory rheumatic diseases. Magyar Reumatológia 50, 68–94 (2009)Google Scholar
  17. 17.
    Péntek, M., Brodszky, V., Gulácsi, A.L., Hajdú, O., van Exel, J., Brouwer, W., et al. Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. Health Expect. (2012)Google Scholar
  18. 18.
    Gulácsi, L., Brodszky, V., Péntek, M., Varga, S., Vas, G., Boncz, I.: History of health technology assessment in Hungary. Int. J. Technol. Assess. Health Care 25(Suppl 1), 120–126 (2009)PubMedGoogle Scholar
  19. 19.
    Gulácsi, L., Boncz, I., Drummond, M.: Issues for countries considering introducing the “fourth hurdle”: the case of Hungary. Int. J. Technol. Assess. Health Care 20(3), 337–341 (2004)PubMedGoogle Scholar
  20. 20.
    Gulácsi, L.: Future challenges for health economics and health technology assessment of biological drugs. Eur. J. Health Econ. 11(3), 235–238 (2010)PubMedGoogle Scholar
  21. 21.
    Gulácsi, L., Orlewska, E., Péntek, M.: Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. Eur. J. Health Econ. 13(5), 525–531 (2012)PubMedGoogle Scholar
  22. 22.
    Brodszky, V., Orlewska, E., Pentek, M., Karpati, K., Skoupa, J., Gulacsi, L.: Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. Med. Sci. Monit. 16(1), SR1–SR5 (2010)PubMedGoogle Scholar
  23. 23.
    Coates, L.C., Cawkwell, L.S., Ng, N.W., Bennett, A.N., Bryer, D.J., Fraser, A.D., et al.: Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 47(6), 897–900 (2008)Google Scholar
  24. 24.
    Pradeep, D.J., Keat, A.C., Gaffney, K., Brooksby, A., Leeder, J., Harris, C.: Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 47(11), 1726–1727 (2008)Google Scholar
  25. 25.
    Hu, S., Liang, S., Guo, H., Zhang, D., Li, H., Wang, X., et al.: Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J. Biol. Chem. 288(38), 27059–27067 (2013)PubMedGoogle Scholar
  26. 26.
    Plasencia, C., Pascual-Salcedo, D., García-Carazo, S., Lojo, L., Nuño, L., Villalba, A., et al.: The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res. Ther. 15(4), R79 (2013)PubMedCentralPubMedGoogle Scholar
  27. 27.
    Garcês, S., Demengeot, J., Benito-Garcia, E.: The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 72(12), 1947–1955 (2013)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Katalin Gulyas
    • 1
  • Nora Bodnar
    • 1
  • Zsofia Nagy
    • 1
  • Szilvia Szamosi
    • 1
  • Agnes Horvath
    • 1
  • Andrea Vancsa
    • 1
  • Edit Vegh
    • 1
  • Zoltan Szabo
    • 1
  • Gabriella Szucs
    • 1
  • Zoltan Szekanecz
    • 1
  • Sandor Szanto
    • 1
  1. 1.Department of Rheumatology, Institute of MedicineUniversity of Debrecen Medical and Health Science CenterDebrecenHungary

Personalised recommendations